The gross proceeds to Dermata from the exercise of the warrants are expected to be approximately $6.2 million, prior to deducting fees and offering expenses.

The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $6.2 million, before deducting financial advisory fees.